Argentina Rejects Key Sofosbuvir Patent Application
Argentina’s patent office, INPI, has rejected an application for a key patent relating to Gilead’s hepatitis C drug Sovaldi (sofosbuvir).
You may also be interested in...
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Access to affordable medicines has become a global challenge. A new chapter has been added to the struggle as several EU-based civil society groups join hands to challenge Gillead’s sofosbuvir patent in a bid to increase access to affordable hepatitis C treatment.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.